Literature DB >> 33906109

Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles.

Tinghong Zhang1, Yunlong Wu2, Dejun Yang3, Cunzao Wu4, Huaqiong Li5.   

Abstract

MicroRNAs play an irreplaceable role in gene expression regulation. Upregulation of several miRNAs increases the risk of invasion and metastasis of breast cancer cells. An oncogenic miRNA, miR-21, is highly expressed in triple-negative breast cancer (TNBC) and is associated with tumor proliferation, invasion, carcinogenesis, prognosis, and therapeutic resistance. However, targeted delivery of therapeutic anti-miRNAs into cancer cells remains challenging, especially for TNBC. In this study, we report the application of an RNA nanotechnology-based platform for the targeted delivery of anti-miR-21 by epidermal growth factor receptor (EGFR) aptamer in vitro to TNBC and chemical-resistant breast cancer cells. RNA nanoparticles reduced cell viability and sensitized breast cancer cells to doxorubicin (DOX) treatment in vitro. Inhibition of miR-21 by RNA nanoparticles suppressed TNBC cell invasion, migration, and colony formation. The results indicate the potential application of nanotechnology-based delivery platforms in clinical anti-cancer therapeutics.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA nanoparticles; Triple-negative breast cancer; miR-21

Year:  2021        PMID: 33906109     DOI: 10.1016/j.bbrc.2021.04.040

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.

Authors:  Mauro Comes Franchini; Laura Cerchia; Lisa Agnello; Silvia Tortorella; Annachiara d'Argenio; Clarissa Carbone; Simona Camorani; Erica Locatelli; Luigi Auletta; Domenico Sorrentino; Monica Fedele; Antonella Zannetti
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.